() has held its Q1 earnings call. Read on for the main highlights of the call. Meet Samuel – Your Personal Investing Prophet. Start a conversation with TipRanks t ...
CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor ...
Q1 2026 Management View “For the first quarter 2026, revenue was $1.6 million compared with $896,000 in Q1 '25, representing an 80% year-over-year revenue growth,” said CEO Brian Carrico, adding it ...
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science ...
Zacks Investment Research has recently initiated coverage of NeurAxis, Inc. NRXS, assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the ...
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
Shares of NeurAxis, Inc. NRXS have gained 2.5% since the company reported earnings for the quarter ended March 31, 2026, ...
Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% ...
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results